Tea tree oil

Tea Tree Oil (Melaleuca alternifolia)

1. Identity

Botanical and Common Names

Tea tree oil is an essential oil derived from the tea tree (Melaleuca alternifolia), a species of tall shrub or tree in the myrtle family (Myrtaceae) originally native to the Bungawalbin Valley in New South Wales, eastern Australia. The plant is also known colloquially as the narrow-leaved paperbark or simply the tea tree. The oil is sometimes called melaleuca oil in reference to its botanical genus. The name "tea tree" is used for several plants, mostly from Australia and New Zealand, from the family Myrtaceae related to the myrtle.

Extraction and Physical Character

Tea tree oil is derived from the leaves of the plant by steam distillation. It is strongly aromatic, having a camphor-like medicinal scent, and ranges from clear to pale yellow in color. It is obtained as an extract from the leaves, branches, and bark of Melaleuca alternifolia Cheel.

Standardization and International Quality Standard

Tea tree oil is defined by the International Standard ISO 4730 ("Oil of Melaleuca, terpinen-4-ol type"), containing terpinen-4-ol, γ-terpinene, and α-terpinene as about 70% to 90% of whole oil, while p-cymene, terpinolene, α-terpineol, and α-pinene collectively account for some 15% of the oil. The composition of oil sold as TTO is regulated by an international standard for "Oil of Melaleuca—terpinen-4-ol type," which sets maxima and/or minima for 14 components of the oil. Notably, the standard does not stipulate the species of Melaleuca from which the TTO must be sourced; instead, it sets out physical and chemical criteria for the desired chemotype.

Chemotypes

Six varieties, or chemotypes, of M. alternifolia have been described, each producing oil with a distinct chemical composition. These include a terpinen-4-ol chemotype, a terpinolene chemotype, and four 1,8-cineole chemotypes. The terpinen-4-ol chemotype typically contains levels of terpinen-4-ol of between 30 to 40% and is the chemotype used in commercial TTO production.

Common Forms and Preparations

This essential oil has been used for almost 100 years in Australia but is now available worldwide both as neat oil and as an active component in an array of products. Commercially, TTO is encountered as:

• Neat (undiluted) essential oil (typically 100%), sold for topical use after dilution
• Topical gels (commonly 5% concentration for acne)
• Creams and lotions (concentrations used in studies range from 5% to 100%)
• Shampoos (commonly 5% for dandruff)
• Eyelid wipes, gels, and scrubs (for Demodex blepharitis)
• Mouthwashes and dental formulations
• Soaps, topical pharmaceuticals, and household products

2. Traditional and Historical Use

Aboriginal Australian Use

The Bundjalung Aboriginal peoples of northern New South Wales were likely the first to use tea tree plants medicinally. Aboriginal oral history reports stories of "healing lakes" containing fallen leaves of the tea tree plant. Aboriginal peoples most likely employed the plant as an herbal remedy, using inhaled oils from crushed leaves to treat upper respiratory infections and infusions to treat skin conditions.

The indigenous Bundjalung people of eastern Australia are believed to have used tea trees as a traditional medicine for many years in a variety of ways including inhaling the oil from the crushed leaves to treat coughs and colds, applying the leaves on wounds as a poultice, as well as brewing an infusion of the leaves to make a tea for treatment of sore throats, or applying leaves on the skin for minor wounds, abrasions, and insect bites and stings.

As a native Australian plant, tea tree has a well-documented history of use by the indigenous Bundjalung people for health and wellness purposes, and the ingredient is ingrained in their culture.

First European Contact and the Name "Tea Tree"

For thousands of years, Aboriginal people used the leaves as an antiseptic and antifungal by crushing the leaves and making a mudpack. However, the plant did not receive the name "tea tree" until 1770, when the name was given by the British explorer Captain James Cook and his crew.

Early Scientific Documentation and Commercialization

The plant's medicinal attributes were first documented in the 1920s by Australian chemist Arthur Penfold in a series of papers that explored the germicidal properties of various Australian essential oils. In 1930 the Medical Journal of Australia published an official report on tea tree oil as a potential new germicide.

By the 1930s and 1940s, tea tree oil was widely celebrated as an antiseptic treatment, and during World War II Australian soldiers were issued with tea tree oil in their first aid kits.

The global tea tree oil industry first began around the 1980s when commercial tea tree plantations started to appear. The oil was mainly used in anti-acne skin care treatments throughout the 1980s, 1990s, and 2000s, but it is now being seen in more unexpected products.

According to a review by Carson and Riley, TTO was applied historically for many purposes including perionychia, empyema, gynaecological conditions, epidermophyton infections, impetigo contagiosum, pediculosis, ringworm, tinea, throat conditions, psoriasis, and mouth conditions.

3. Key Constituents and Active Compounds

Primary Constituents

The major constituents of commercial TTO are terpinen-4-ol, γ-terpinene, 1,8-cineole, α-terpinene, α-terpineol, p-cymene, and α-pinene. Terpinen-4-ol (a monocyclic terpene alcohol) is the primary component of the essential oil of Melaleuca alternifolia (tea tree oil), typically representing about 40% of the total oil composition.

The antimicrobial activity of TTO is attributed mainly to terpinen-4-ol, a major component of the oil. Consequently, to optimize antimicrobial activity, a lower limit of 30% and no upper limit were set for terpinen-4-ol content under the ISO standard.

Role of Other Components

The antimicrobial activity of TTO that can be attributed to the loss of membrane integrity and function is not only attributed to the amount of terpinen-4-ol, but to the complex interaction among different components such as 1,8-cineole, α-terpinene, γ-terpinene, terpinolene, and others. Given the heterogeneous composition of TTO and the antimicrobial activities of many of its components, it seems unlikely that there is only one mechanism of action or that only one component is responsible for the antimicrobial action.

Terpinen-4-ol: Chemical Identity

Terpinen-4-ol is an isomer of terpineol with the chemical formula C₁₀H₁₈O. It is classified as a monocyclic monoterpene alcohol. Its IUPAC name is 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol; its CAS number is 562-74-3. Terpinen-4-ol is a naturally occurring monoterpene alcohol with good antimicrobial properties; it is effective against methicillin-resistant S. aureus and fluconazole-resistant C. albicans.

4. Established Mechanisms of Action

Antimicrobial: Membrane Disruption

The mechanism of action of TTO against bacteria has now been partly elucidated. Prior to the availability of data, assumptions about its mechanism of action were made on the basis of its hydrocarbon structure and attendant lipophilicity. Since hydrocarbons partition preferentially into biological membranes and disrupt their vital functions, TTO and its components were also presumed to behave in this manner. This premise is further supported by data showing that TTO permeabilizes model liposomal systems.

In Escherichia coli, S. aureus, and C. albicans, Cox et al. concluded that the antimicrobial activity of TTO results from its ability to disrupt the permeability barrier of microbial membrane structures, similar to that of other disinfectants and preservatives such as phenol derivatives and chlorhexidine. TTO penetrated through the cell walls and cytoplasmic membranes of E. coli, S. aureus, C. albicans, and Aspergillus niger, damaging these structures with subsequent loss of cytoplasm content and cell death.

The mechanisms of action of tea tree oil and three of its components — 1,8-cineole, terpinen-4-ol, and α-terpineol — against Staphylococcus aureus ATCC 9144 were investigated. Treatment with these agents, particularly terpinen-4-ol and α-terpineol, reduced the viability of S. aureus. None of the agents caused lysis as determined by measurement of optical density, although cells became disproportionately sensitive to subsequent autolysis.

Anti-inflammatory Mechanisms

In vitro work has demonstrated that TTO affects a range of immune responses. The water-soluble components of TTO can inhibit the lipopolysaccharide (LPS)-induced production of the inflammatory mediators TNF-α, IL-1β, and IL-10 by human peripheral blood monocytes by approximately 50%, and prostaglandin E₂ by about 30% after 40 hours. Further examination of the water-soluble fraction of TTO identified terpinen-4-ol, α-terpineol, and 1,8-cineole as the main components, but of these, only terpinen-4-ol was able to diminish the production of TNF-α, IL-1β, IL-8, IL-10, and prostaglandin E₂ by LPS-activated monocytes.

The water-soluble fraction of TTO, terpinen-4-ol, and α-terpineol also suppressed superoxide production by agonist-stimulated monocytes but not neutrophils.

In vivo studies using mice showed that terpinen-4-ol (5, 10, 20 mg/kg), given intraperitoneally, significantly inhibited LPS-induced inflammatory cytokines (TNF-α and IL-1β) through the suppression of phosphorylation of NF-κB p65 and IκBα in the bronchoalveolar lavage fluid of LPS-induced acute lung injury mice. Terpinen-4-ol dose-dependently increased the expression of PPAR-γ, a nuclear receptor involved in the attenuation of NF-κB activation and the regulation of the inflammatory response.

Antifungal Mechanisms

The mechanism underlying TTO antifungal activity is not fully understood. A comprehensive metabolomics survey undertaken to identify changes in metabolite production in Botrytis cinerea cells treated with TTO found significant differences in 91 metabolites, including 8 upregulated and 83 downregulated metabolites. The results indicate that TTO inhibits primary metabolic pathways through suppression of the tricarboxylic acid (TCA) cycle and fatty acid metabolism.

5. Scientific Evidence by Area of Use

5.1 Acne Vulgaris

Tea tree oil is an essential oil extracted from Melaleuca alternifolia with known antibacterial, anti-inflammatory, and antioxidant properties, making it a candidate for the treatment of acne.

Three trials tested the effect of tea tree oil-based gels containing 5%–6% tea tree oil on acne lesion counts and acne severity in subjects with mild to moderate acne vulgaris. Bassett et al. (1990) compared a 5% tea tree oil gel to a 5% benzoyl peroxide lotion in 124 subjects aged 12–35 years. Both treatments significantly reduced the number of inflamed and non-inflamed acne lesions.

Patients with mild-to-moderate acne were prescribed 5% water-based TTO gel or 5% water-based benzoyl peroxide lotion, both applied daily for 3 months. Lesions decreased with both treatments but inflamed lesions were significantly better with benzoyl peroxide compared with TTO; non-inflamed lesions were comparable. Fewer patients experienced adverse events with TTO (44% versus 79%).

A 2023 review highlighted that tea tree oil has antibacterial, anti-inflammatory, and antioxidant properties, which may help reduce the amount of inflammatory lesions such as papules and pustules. However, the authors noted that further large-scale, high-quality studies on the topic are necessary.

Evidence strength: A small amount of research suggests that tea tree oil might be helpful for acne, but more evidence is needed before definite conclusions can be reached.

5.2 Fungal Nail Infection (Onychomycosis)

Patients with subungual onychomycosis received either 100% TTO or 1% clotrimazole twice daily for 6 months. At the end of trial, 18% of TTO-treated patients and 11% of control patients had negative cultures. Full or partial resolution of symptoms was experienced by 60% and 61% of patients, respectively. At 3-month follow-up, these figures had declined to 56% and 55%, respectively. None of these differences were statistically significant.

A second onychomycosis trial (n=60) compared 2% butenafine hydrochloride combined with 5% TTO cream versus a cream of TTO only for toenail onychomycosis, applied three times daily for 8 weeks.

Tea tree oil was the most well-studied complementary therapy for onychomycosis, but was utilized in multiple different formulations. Many studies did not have a control group, and few studies compared the intervention to an approved topical or oral antifungal.

Evidence strength: A 2024 review suggested that, overall, there is weak evidence to support the use of tea tree oil to treat onychomycosis. The authors noted that larger clinical trials are necessary to establish the safety and efficacy of tea tree oil. While preliminary evidence exists for several complementary and alternative therapies in the treatment of onychomycosis, large-scale, randomized, placebo-controlled trials are needed prior to endorsing their use to patients.

5.3 Tinea Pedis (Athlete's Foot)

Patients with tinea pedis (proven by culture) were prescribed 10% TTO cream, 1% tolnaftate cream, or placebo cream, all applied twice daily for 4 weeks. Clinical data show beneficial effects in treating tinea pedis.

A 2021 study highlighted that tea tree oil has antifungal properties which may help kill fungal pathogens. The authors theorized that it may help treat athlete's foot alongside antifungal medications. However, they also noted that investigation into the efficacy and safety of this theory is necessary.

Evidence strength: Preliminary; limited clinical trials with small samples; confirmatory large RCTs are lacking.

5.4 Demodex Blepharitis

Fourteen papers dealing with the use of TTO to treat chronic blepharitis were found in a literature review from 2012 to December 2021. The effectiveness of TTO treatment was tested in vitro by 4 authors and in vivo by 10 authors. All studies confirmed efficacy of TTO treatment, even cyclic, on Demodex mite blepharitis. TTO can be used for lid scrubs, facial cleanser, eyelid patch, eyelid gel, eyelash shampoo, or, more commonly, as TTO-impregnated eyelid wipes.

A 2020 Cochrane review suggests that there is uncertainty related to the effectiveness of 5% to 50% tea tree oil for the short-term treatment of Demodex blepharitis; however, if used, lower concentrations may be preferable in the eye care arena to avoid induced ocular irritation.

No RCTs in the Cochrane review provided data on mean change in number of cylindrical dandruff or the proportion of participants experiencing conjunctival injection or meibomian gland dysfunction. Three RCTs provided information on adverse events; one reported no adverse events. The other two described a total of six participants treated with tea tree oil who experienced ocular irritation or discomfort that resolved with re-educating the patient on application techniques and continuing use. The certainty of the evidence for this outcome was graded as very low.

Evidence strength: Preliminary and uncertain. The 2020 Cochrane review rated the evidence certainty as very low. Larger, well-controlled RCTs are needed.

5.5 Dandruff (Seborrheic Dermatitis of the Scalp)

Dandruff is caused by a buildup of sebum, dry skin, and fungus on the scalp. Studies show that a 5% concentration of tea tree oil in shampoos can reduce flaking, itchiness, and greasiness. TTO has been clinically evaluated for the treatment of dandruff.

Evidence strength: Limited; a small number of RCTs, primarily using 5% TTO shampoo formulations, show positive results, but the overall evidence base is modest.

5.6 MRSA Decolonization and Wound Infections

A case report described a combination of plant extracts of which TTO was a major component being inserted percutaneously into bone to treat an intractable MRSA infection of the lower tibia, which subsequently resolved.

There has been one short report of induced in vitro resistance to TTO in S. aureus. Stepwise exposure of five MRSA isolates to increasing concentrations of TTO yielded three isolates with TTO MICs of 1% and one isolate each with TTO MICs of 2% and 16%, respectively.

Evidence strength: Primarily in vitro and limited case reports; no sufficiently powered clinical trials have been completed to confirm clinical efficacy for MRSA decolonization.

5.7 Oral Health (Gingivitis and Periodontal Disease)

A small 2020 study found that tea tree oil mouthwash was slightly more effective than chlorhexidine mouthwash in treating gingivitis.

A 2024 systematic review and meta-analysis published in Oral Health & Preventive Dentistry examined the effect of local application of tea tree oil adjunctive to daily oral maintenance and nonsurgical periodontal treatment. This review is referenced in the NCCIH literature but specific pooled data are not fully available from open-access sources.

Evidence strength: Preliminary; small studies with mixed comparators; insufficient evidence for a definitive clinical recommendation.

5.8 Vaginal Infections

In one case report, a woman self-treated successfully with a 5-day course of TTO pessaries after having been clinically diagnosed with bacterial vaginosis. Recent investigations on the antifungal properties of TTO have been performed with reference to the treatment of vaginal candidiasis; however, there is a lack of in vivo data supporting in vitro results.

Evidence strength: Very limited; largely in vitro and isolated case reports. No sufficiently powered RCTs exist.

5.9 Antiparasitic Activity (Ectoparasites)

A systematic review to assess preclinical and clinical studies focused on the antiparasitic activity of TTO against Demodex mites, scabies mites, house dust mites, lice, fleas, chiggers, and bed bugs revealed the efficacy of TTO and its components against ectoparasites of medical importance. Such results can justify the use of TTO in the pharmacotherapy of ectoparasitic infections.

Evidence strength: Mostly in vitro and limited in vivo; clinical evidence is insufficient to confirm routine clinical use.

6. Body Systems and Health Areas Associated with Tea Tree Oil

• Integumentary System (Skin): Acne, dandruff, seborrheic dermatitis, contact dermatitis (both causative agent and possible treatment), tinea pedis, wound care, insect bites
• Musculoskeletal/Nail: Onychomycosis (fungal nail infection)
• Ophthalmic: Demodex blepharitis, meibomian gland dysfunction
• Oral/Dental: Gingivitis, periodontal disease, oral candidiasis
• Reproductive/Genitourinary: Vaginal candidiasis, bacterial vaginosis (case reports and in vitro only)
• Immunological: Modulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-8, PGE₂) — established in vitro and in animal models
• Infectious Disease: MRSA and other antibiotic-resistant organisms (primarily in vitro)

7. Dosage Forms and Dosages Reported in Studies

The following dosages are reported as used in specific studies and clinical trials; they are not recommendations:

• Acne vulgaris: In one trial (n=124), patients used 5% water-based TTO gel applied daily for 3 months. Three trials tested tea tree oil-based gels containing 5%–6% tea tree oil on acne lesion counts.
• Tinea pedis: Patients were prescribed 10% TTO cream applied twice daily for 4 weeks.
• Onychomycosis: Patients received either 100% TTO or 1% clotrimazole twice daily for 6 months. A second trial used 2% butenafine hydrochloride and 5% TTO cream or TTO cream only, applied three times daily for 8 weeks.
• Demodex blepharitis: Studies have used concentrations ranging from 5% to 50% tea tree oil.
• Dandruff: Studies have used a 5% concentration of tea tree oil in shampoos.
• Anti-inflammatory (in vitro/animal): The water-soluble components of tea tree oil at concentrations equivalent to 0.125% significantly suppressed LPS-induced production of TNF-α, IL-1β, and IL-10 by approximately 50% and PGE₂ by approximately 30% after 40 hours.
• Anti-inflammatory (animal model): Terpinen-4-ol at 5, 10, and 20 mg/kg intraperitoneally was used in murine acute lung injury models.

8. Safety Considerations and Notable Interactions

Oral Toxicity

It was concluded that tea tree oil should never be administered orally, as it can lead to central nervous system depression and pneumonitis. Reported effects following oral intake include disorientation, systemic contact dermatitis, neutrophil leukocytosis, and coma.

Contact Dermatitis and Allergic Reactions

Of all essential oils, TTO has caused the most published allergic reactions since the first cases were reported in 1991. In routine testing, prevalences of positive patch test reactions have ranged from 0.1% to 3.5%.

The occurrence of dermatitis was more common in persons prone to allergic reactions, for example those who already suffer from a skin disease. It has been suggested that contact dermatitis due to tea tree oil may be caused by the formation of monoterpene oxidation products like peroxides, epoxides, and endoperoxides due to exposure of the oil to heat, light, or oxygen.

Fresh TTO is a weak to moderate sensitizer, but oxidation increases its allergenic potency. Skin irritation following use of tea tree oil is due to its auto-oxidation and formation of epoxide intermediates via arene-epoxidation reactions catalyzed by human cytochrome P450 enzymes.

Ocular Safety

In clinical trials of TTO for blepharitis, some participants experienced ocular irritation or discomfort that resolved with re-educating the patient on application techniques. Lower concentrations are generally preferred for periocular application to minimize the risk of irritation.

Potential Endocrine Effects

In vitro studies indicate that tea tree oil has weak estrogenic and antiandrogenic properties that may alter estrogen and androgen signaling pathways. At the same time, the notion that tea tree oil has hormone-modulating properties has been challenged, and further confirmatory research is needed.

One study observed that tea tree oil disrupted at least one of several studied hormones in human placental cell bioassays, but the EOs appear to be hormonal modulators rather than endocrine-disrupting chemicals (EDCs). Clinical evidence is doubtful and unlikely to support the proposed link between tea tree oil and endocrine disruption in children, due to the actual absence of these ingredients in the offending products in case reports.

Potential for Resistance

There has been one short report of induced in vitro resistance to TTO in S. aureus. Stepwise exposure of five MRSA isolates to increasing concentrations of TTO yielded resistance at varying MIC levels. The clinical significance of this finding remains uncertain and has not been demonstrated in vivo.

Storage Considerations

Contact dermatitis due to tea tree oil may be caused by the formation of monoterpene oxidation products like peroxides, epoxides, and endoperoxides due to exposure of the oil to heat, light, or oxygen. Proper storage in sealed, dark containers is therefore relevant to preserving both quality and reducing allergenicity.

General Evidence Context

The National Center for Complementary and Integrative Health (NCCIH) advises that research into the effects of topical tea tree oil on people is limited. While the body of in vitro and preclinical data is substantial, many clinical areas lack large, well-controlled RCTs, and the overall evidence for most therapeutic applications remains preliminary or inconclusive.

References

• Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (Tea Tree) Oil: a Review of Antimicrobial and Other Medicinal Properties. Clinical Microbiology Reviews. 2006;19(1):50–62. PMC/NIH
• National Center for Complementary and Integrative Health (NCCIH). Tea Tree Oil: Usefulness and Safety.
• Nascimento T, et al. Tea Tree Oil: Properties and the Therapeutic Approach to Acne—A Review. PMC/MDPI. 2023.
• Ernst E, Huntley A. Tea tree oil: a systematic review of randomized clinical trials. DARE Quality-Assessed Reviews. NCBI Bookshelf.
• Yousefian F, et al. Complementary and Alternative Therapies for Onychomycosis: A Systematic Review of the Clinical Evidence. PMC. 2022.
• Savla K, Le JT, Pucker AD. Tea tree oil for Demodex blepharitis. Cochrane Database of Systematic Reviews. 2020;(6):CD013333. PubMed/NIH.
• Savla K, Le JT, Pucker AD. Tea tree oil for Demodex blepharitis. PMC Full Text. 2020.
• Fromm M, et al. Recent Evidence of Tea Tree Oil Effectiveness in Blepharitis Treatment. PMC. 2022.
• Warshaw EM, et al. Tea tree oil: contact allergy and chemical composition. PubMed. 2016.
• Kowalczyk A, et al. Chemical and Biological Characterization of Melaleuca alternifolia Essential Oil. PMC. 2022.
• Carson CF, et al. Mechanism of Action of Melaleuca alternifolia (Tea Tree) Oil on Staphylococcus aureus Determined by Time-Kill, Lysis, Leakage, and Salt Tolerance Assays and Electron Microscopy. PMC. 2002.
• Carson CF, et al. Mechanism of Action of Tea Tree Oil on Staphylococcus aureus. Antimicrobial Agents and Chemotherapy. 2002.
• Kairey L, et al. Efficacy and safety of Melaleuca alternifolia (tea tree) oil for human health—A systematic review of randomized controlled trials. Frontiers in Pharmacology. 2023.
• Hart PH, et al. Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia, suppresses inflammatory mediator production by activated human monocytes. Inflammation Research. 2000;49:619–626.
• Masyita A, et al. Tea tree oil, a vibrant source of neuroprotection via neuroinflammation inhibition. PMC. 2023.
• Wölfle U, et al. Safety assessment and adverse drug reaction reporting of tea tree oil (Melaleuca aetheroleum). Phytotherapy Research. 2022.
• Memorial Sloan Kettering Cancer Center. Tea Tree Oil: Integrative Medicine Herb Database.
• Shao X, et al. Metabolomic Analysis and Mode of Action of Metabolites of Tea Tree Oil Involved in the Suppression of Botrytis cinerea. PMC. 2017.
• Mondello F, et al. In vivo activity of terpinen-4-ol against azole-susceptible and -resistant human pathogenic Candida species. PMC. 2006.
• Becker LC, et al. Evaluation of Placental Toxicity of Five Essential Oils and Their Potential Endocrine-Disrupting Effects. PMC. 2022.
• Encyclopædia Britannica. Tea tree oil: Description, Uses, Extraction, History, & Side Effects.
• Zhang Y, et al. Tea Tree Essential Oil Kills Escherichia coli and Staphylococcus epidermidis Persisters. PMC. 2023.
• Maissa C, et al. The use of tea tree oil in treating blepharitis and meibomian gland dysfunction. PMC. 2018.
• Ren Z, et al. Tea Tree Oil Terpinen-4-ol Protects Gut Barrier Integrity by Upregulation of Tight Junction Proteins via the ERK1/2-Signaling Pathway. PMC. 2022.
• Ferracini MP, et al. Evaluating efficacy, safety, and innovation in skin care applications of essential oils: a systematic review. Frontiers in Medicine. 2025.